“SpectraCure is on the verge of commercialization, a new exciting step in the company's development. Johan Folkunger has a solid background in this field and is recognized as a very driven professional. With his experience in business development and leadership and his knowledge about how to move a product from the stage of development to commercialization, he will be an essential contribution to our team for the next phase of the company's development. I am very pleased with this recruitment," says Ingemar Kihlström, SpectraCure’s Chairman of the Board.
”Masoud Khayyami, who has acted as CEO until now, continues his ownership and will remain in the company through his seat on the Board of Directors. The company thus continues to benefit from Masoud’s strong commitment, wide network of contacts and unique entrepreneurship. This is a major asset,” says Ingemar Kihlström.
"I look forward to continuing the development of the company together with SpectraCure’s team and Board of Directors, building on the solid foundation laid down thus far. The need for cost-efficient and low-impact cancer treatments is great, and the company's treatment system has a significant potential. I look forward to being part of the company's journey moving forward,” says Johan Folkunger.
"I welcome Johan Folkunger to the company and look forward to playing a continued part in the company's development – but now in a new role, as a very active member of the board and owner," says Masoud Khayyami, who will remain as CEO until Johan Folkunger assumes his new role no later than June 16, 2021.
This information is information that SpectraCure AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08:45 a.m. on March 15, 2021.
For more information, please contact
SpectraCure AB (publ), Chairman of the Board Ingemar Kihlström, telephone: +46(0) 73 382 11 02.
SpectraCure was founded in 2003 as a spin off from Lund University and LTH Faculty of Engineering. The company focuses on cancer treatments with medical systems based on laser light sources, connected to the tumour by way of optical fibers, in combination with a photoreactive drug. The method is referred to as Interstitial Photodynamic Therapy, PDT. The treatment is suitable for internal solid tumours of various kind, such as prostate and pancreatic tumours, but also for example for cancers of the head and neck. www.spectracure.com.
The Company is listed in the Premier segment at Nasdaq First North Growth Market with G&W Fondkommission as the Company’s Certified Adviser, ca@gwkapital.se,tel. +46(0) 8 503 00 050. The share is traded under the ticker SPEC.
